<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436254</url>
  </required_header>
  <id_info>
    <org_study_id>6532</org_study_id>
    <secondary_id>NCI-2010-00869</secondary_id>
    <secondary_id>RG1704001</secondary_id>
    <nct_id>NCT00436254</nct_id>
    <nct_alias>NCT00194662</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer</brief_title>
  <official_title>A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells.&#xD;
      Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in&#xD;
      bone marrow or peripheral blood. Giving vaccine therapy together with sargramostim may be an&#xD;
      effective treatment for breast cancer and ovarian cancer. PURPOSE: This phase I trial is&#xD;
      studying the side effects and identifying the best dose of vaccine therapy when given&#xD;
      together with sargramostim in treating patients with stage III-IV breast cancer or ovarian&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To determine the safety of intradermal administration of 3 doses of a&#xD;
      plasmid-based DNA vaccine encoding the ICD of HER2 administered with a fixed dose of GM-CSF.&#xD;
      II. To determine whether a plasmid DNA vaccine encoding the ICD of HER2 can elicit HER2&#xD;
      specific immune responses. SECONDARY OBJECTIVES: I. To determine if the dose of the&#xD;
      plasmid-based DNA vaccine effects immunologic responses. II. To determine the persistence of&#xD;
      DNA at the site of vaccination. OUTLINE: This is a dose-escalation study of a plasmid-based&#xD;
      DNA (pNGVL3-hICD) vaccine. Patients receive pNGVL3-hICD vaccine admixed with GM-CSF&#xD;
      intradermally once a month for 3 months in the absence of disease progression or unacceptable&#xD;
      toxicity. After completion of study treatment, patients are followed up periodically for up&#xD;
      to 15 years with primary physicians.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by NCI CTCAE v 3.0</measure>
    <time_frame>From baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>From baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of dose on immunologic response</measure>
    <time_frame>From baseline to month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of DNA at the injection site</measure>
    <time_frame>At 1 and 6 months after last vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Stage III Ovarian Epithelial Cancer</condition>
  <condition>Stage III Ovarian Germ Cell Tumor</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Ovarian Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pNGVL3-hICD vaccine</intervention_name>
    <description>Plasmid-based DNA vaccine, given intradermally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given intradermally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>granulocyte macrophage colony-stimulating factor</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
    <other_name>rhu GM-CFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>immunological laboratory methods</other_name>
    <other_name>laboratory methods, immunological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <description>Undergo ELIspot (correlative studies)</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>immunoenzyme techniques</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>Undergo ELISA (correlative studies)</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Undergo punch biopsy (correlative studies)</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Breast cancer: stage III or stage IV breast cancer with metastasis in remission and&#xD;
             defined as NED (no evidence of disease); stable or healing bone disease by radiologic&#xD;
             evaluation which may include, but is not limited to, bone scan, MRI, or PET scan&#xD;
             documented within 90 days of enrollment to study and NED status for extraskeletal&#xD;
             metastasis&#xD;
&#xD;
          -  Ovarian cancer: stage III or stage IV ovarian cancer in first complete remission with&#xD;
             a normal AND stable CA-125; thus, two sequential normal CA-125 values will need to be&#xD;
             documented; a minimum of 30 days between 2 sequential CA-125 values; the most recent&#xD;
             will be within 2 weeks of enrollment into study&#xD;
&#xD;
          -  HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in their primary tumor&#xD;
             or metastasis, and if overexpression is 2+ by IHC or in the absence of IHC, then&#xD;
             patients must have documentation of HER2 gene amplification by FISH&#xD;
&#xD;
          -  Eligible subjects must have completed appropriate treatment for their primary disease&#xD;
             and be off cytotoxic chemotherapy and corticosteroids for at least 1 month prior to&#xD;
             enrollment; patients with stage III/IV breast cancer who have completed chemotherapy&#xD;
             and are continued on trastuzumab monotherapy are eligible; hormonal and bisphosphanate&#xD;
             therapies are allowed&#xD;
&#xD;
          -  Subjects must have a Performance Status Score (Zubrod/ECOG Scale) = 0&#xD;
&#xD;
          -  All subjects must no longer be able to bear children&#xD;
&#xD;
          -  Hematocrit &gt;= 30&#xD;
&#xD;
          -  Platelet count &gt;= 100,000&#xD;
&#xD;
          -  WBC &gt;= 3,000/ul&#xD;
&#xD;
          -  Creatinine =&lt; 2.0 or creatinine clearance &gt;= 60 ml/minute&#xD;
&#xD;
          -  Serum bilirubin &lt; 1.5 mg/dl&#xD;
&#xD;
          -  SGOT &lt; 2 x ULN&#xD;
&#xD;
          -  Subjects must have recovered from major infections and/or surgical procedures and, in&#xD;
             the opinion of the investigator, not have a significant active concurrent medical&#xD;
             illness precluding protocol treatment or survival&#xD;
&#xD;
          -  Normal ANA, anti-dsDNA and C3&#xD;
&#xD;
          -  Patients on trastuzumab monotherapy must have adequate cardiac function as&#xD;
             demonstrated by normal ejection fraction (EF) of MUGA scan or echocardiogram&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects cannot be simultaneously enrolled on other treatment studies&#xD;
&#xD;
          -  Any contraindication to receiving GM-CSF based vaccine products&#xD;
&#xD;
          -  Prior known history of cardiac disease, specifically restrictive cardiomyopathy,&#xD;
             unstable angina within the last 6 months prior to enrollment, New York Heart&#xD;
             Association functional class III-IV heart or symptomatic pericardial effusion&#xD;
&#xD;
          -  Prior known history of pulmonary disease other than controlled asthma&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
&#xD;
          -  Subjects cannot have active immunodeficiency disorder, e.g., HIV&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary L. Disis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Germinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

